nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—Fingolimod—multiple sclerosis	0.127	0.246	CbGbCtD
Conivaptan—CYP3A4—Methylprednisolone—multiple sclerosis	0.0817	0.158	CbGbCtD
Conivaptan—CYP3A4—Triamcinolone—multiple sclerosis	0.062	0.12	CbGbCtD
Conivaptan—CYP3A4—Mitoxantrone—multiple sclerosis	0.0596	0.116	CbGbCtD
Conivaptan—CYP3A4—Betamethasone—multiple sclerosis	0.0532	0.103	CbGbCtD
Conivaptan—CYP3A4—Prednisolone—multiple sclerosis	0.0524	0.102	CbGbCtD
Conivaptan—CYP3A4—Prednisone—multiple sclerosis	0.0495	0.0959	CbGbCtD
Conivaptan—CYP3A4—Dexamethasone—multiple sclerosis	0.0309	0.0599	CbGbCtD
Conivaptan—Infusion site reaction—Cladribine—multiple sclerosis	0.0242	0.0921	CcSEcCtD
Conivaptan—Oral candidiasis—Cladribine—multiple sclerosis	0.00589	0.0224	CcSEcCtD
Conivaptan—Pneumonia—Fingolimod—multiple sclerosis	0.00371	0.0141	CcSEcCtD
Conivaptan—Infestation—Fingolimod—multiple sclerosis	0.00369	0.0141	CcSEcCtD
Conivaptan—Infestation NOS—Fingolimod—multiple sclerosis	0.00369	0.0141	CcSEcCtD
Conivaptan—Candida infection—Cladribine—multiple sclerosis	0.00357	0.0136	CcSEcCtD
Conivaptan—Sepsis—Cladribine—multiple sclerosis	0.00325	0.0124	CcSEcCtD
Conivaptan—Phlebitis—Cladribine—multiple sclerosis	0.00315	0.012	CcSEcCtD
Conivaptan—Cardiac disorder—Fingolimod—multiple sclerosis	0.00308	0.0117	CcSEcCtD
Conivaptan—Angiopathy—Fingolimod—multiple sclerosis	0.00301	0.0115	CcSEcCtD
Conivaptan—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00299	0.0114	CcSEcCtD
Conivaptan—Mental disorder—Fingolimod—multiple sclerosis	0.0029	0.0111	CcSEcCtD
Conivaptan—Atrial fibrillation—Cladribine—multiple sclerosis	0.00287	0.0109	CcSEcCtD
Conivaptan—Cardiac failure—Cladribine—multiple sclerosis	0.00278	0.0106	CcSEcCtD
Conivaptan—Hypertension—Fingolimod—multiple sclerosis	0.00249	0.00949	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00244	0.00929	CcSEcCtD
Conivaptan—Infection—Fingolimod—multiple sclerosis	0.00234	0.00891	CcSEcCtD
Conivaptan—Nervous system disorder—Fingolimod—multiple sclerosis	0.00231	0.0088	CcSEcCtD
Conivaptan—Skin disorder—Fingolimod—multiple sclerosis	0.00229	0.00871	CcSEcCtD
Conivaptan—Hypotension—Fingolimod—multiple sclerosis	0.0022	0.00838	CcSEcCtD
Conivaptan—Sepsis—Mitoxantrone—multiple sclerosis	0.00213	0.00813	CcSEcCtD
Conivaptan—Pneumonia—Cladribine—multiple sclerosis	0.0021	0.00802	CcSEcCtD
Conivaptan—Infestation NOS—Cladribine—multiple sclerosis	0.00209	0.00797	CcSEcCtD
Conivaptan—Infestation—Cladribine—multiple sclerosis	0.00209	0.00797	CcSEcCtD
Conivaptan—Phlebitis—Mitoxantrone—multiple sclerosis	0.00207	0.00789	CcSEcCtD
Conivaptan—Urinary tract infection—Cladribine—multiple sclerosis	0.00203	0.00775	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00203	0.00774	CcSEcCtD
Conivaptan—Urinary tract disorder—Cladribine—multiple sclerosis	0.00185	0.00707	CcSEcCtD
Conivaptan—Oedema peripheral—Cladribine—multiple sclerosis	0.00185	0.00705	CcSEcCtD
Conivaptan—Urethral disorder—Cladribine—multiple sclerosis	0.00184	0.00702	CcSEcCtD
Conivaptan—Cardiac failure—Mitoxantrone—multiple sclerosis	0.00183	0.00697	CcSEcCtD
Conivaptan—Hyponatraemia—Mitoxantrone—multiple sclerosis	0.00179	0.00683	CcSEcCtD
Conivaptan—Candida infection—Triamcinolone—multiple sclerosis	0.00177	0.00675	CcSEcCtD
Conivaptan—Cardiac disorder—Cladribine—multiple sclerosis	0.00174	0.00664	CcSEcCtD
Conivaptan—Pneumonia—Azathioprine—multiple sclerosis	0.00171	0.00652	CcSEcCtD
Conivaptan—Angiopathy—Cladribine—multiple sclerosis	0.0017	0.00649	CcSEcCtD
Conivaptan—Infestation—Azathioprine—multiple sclerosis	0.0017	0.00648	CcSEcCtD
Conivaptan—Infestation NOS—Azathioprine—multiple sclerosis	0.0017	0.00648	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.0017	0.00767	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Cladribine—multiple sclerosis	0.00169	0.00645	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.00168	0.00761	CbGpPWpGaD
Conivaptan—Pruritus—Fingolimod—multiple sclerosis	0.00167	0.00635	CcSEcCtD
Conivaptan—Dehydration—Mitoxantrone—multiple sclerosis	0.00166	0.00632	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—S1PR1—multiple sclerosis	0.00165	0.00745	CbGpPWpGaD
Conivaptan—Mental disorder—Cladribine—multiple sclerosis	0.00165	0.00627	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—S1PR1—multiple sclerosis	0.00164	0.0074	CbGpPWpGaD
Conivaptan—Malnutrition—Cladribine—multiple sclerosis	0.00164	0.00623	CcSEcCtD
Conivaptan—Erythema—Cladribine—multiple sclerosis	0.00164	0.00623	CcSEcCtD
Conivaptan—Hypokalaemia—Mitoxantrone—multiple sclerosis	0.00162	0.00619	CcSEcCtD
Conivaptan—Diarrhoea—Fingolimod—multiple sclerosis	0.00161	0.00614	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.0016	0.00722	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.0016	0.00722	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00159	0.00717	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00159	0.00717	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00159	0.00716	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00159	0.00716	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.00158	0.00713	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.00157	0.00708	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00153	0.00693	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00152	0.00688	CbGpPWpGaD
Conivaptan—Anaemia—Cladribine—multiple sclerosis	0.00151	0.00576	CcSEcCtD
Conivaptan—Headache—Fingolimod—multiple sclerosis	0.00147	0.00562	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.00145	0.00655	CbGpPWpGaD
Conivaptan—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.0014	0.00634	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Mitoxantrone—multiple sclerosis	0.00139	0.0053	CcSEcCtD
Conivaptan—Pneumonia—Mitoxantrone—multiple sclerosis	0.00138	0.00527	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00138	0.00527	CcSEcCtD
Conivaptan—Cardiac failure—Methylprednisolone—multiple sclerosis	0.00138	0.00525	CcSEcCtD
Conivaptan—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00138	0.00524	CcSEcCtD
Conivaptan—Confusional state—Cladribine—multiple sclerosis	0.00135	0.00513	CcSEcCtD
Conivaptan—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.00134	0.00509	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—GPR65—multiple sclerosis	0.00133	0.00601	CbGpPWpGaD
Conivaptan—Infection—Cladribine—multiple sclerosis	0.00133	0.00505	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—GPR65—multiple sclerosis	0.00132	0.00597	CbGpPWpGaD
Conivaptan—Haematuria—Mitoxantrone—multiple sclerosis	0.00131	0.005	CcSEcCtD
Conivaptan—Nervous system disorder—Cladribine—multiple sclerosis	0.00131	0.00499	CcSEcCtD
Conivaptan—Skin disorder—Cladribine—multiple sclerosis	0.0013	0.00494	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00128	0.00578	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00128	0.00576	CbGpPWpGaD
Conivaptan—Sepsis—Prednisone—multiple sclerosis	0.00127	0.00485	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00127	0.00574	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00127	0.00572	CbGpPWpGaD
Conivaptan—Cardiac failure—Dexamethasone—multiple sclerosis	0.00125	0.00477	CcSEcCtD
Conivaptan—Cardiac failure—Betamethasone—multiple sclerosis	0.00125	0.00477	CcSEcCtD
Conivaptan—Hypotension—Cladribine—multiple sclerosis	0.00125	0.00475	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00123	0.00558	CbGpPWpGaD
Conivaptan—Anaemia—Azathioprine—multiple sclerosis	0.00123	0.00468	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00123	0.00554	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCR1—multiple sclerosis	0.00122	0.0055	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CXCL13—multiple sclerosis	0.00122	0.0055	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR1—multiple sclerosis	0.00121	0.00546	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCL13—multiple sclerosis	0.00121	0.00546	CbGpPWpGaD
Conivaptan—Insomnia—Cladribine—multiple sclerosis	0.00121	0.0046	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.0012	0.00543	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00119	0.00539	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00115	0.00439	CcSEcCtD
Conivaptan—Pain—Cladribine—multiple sclerosis	0.00114	0.00435	CcSEcCtD
Conivaptan—Constipation—Cladribine—multiple sclerosis	0.00114	0.00435	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00114	0.00514	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00113	0.00511	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00112	0.00428	CcSEcCtD
Conivaptan—Hypokalaemia—Betamethasone—multiple sclerosis	0.00111	0.00424	CcSEcCtD
Conivaptan—Hypokalaemia—Dexamethasone—multiple sclerosis	0.00111	0.00424	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00111	0.00501	CbGpPWpGaD
Conivaptan—Urine output increased—Methotrexate—multiple sclerosis	0.00111	0.00422	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.0011	0.00497	CbGpPWpGaD
Conivaptan—Feeling abnormal—Cladribine—multiple sclerosis	0.0011	0.00419	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.0011	0.00497	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.0011	0.00496	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.0011	0.00495	CbGpPWpGaD
Conivaptan—Cardiac failure—Prednisone—multiple sclerosis	0.00109	0.00415	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00109	0.00492	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00109	0.00491	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—POMC—multiple sclerosis	0.00108	0.00488	CbGpPWpGaD
Conivaptan—Infection—Azathioprine—multiple sclerosis	0.00108	0.00411	CcSEcCtD
Conivaptan—Erythema—Mitoxantrone—multiple sclerosis	0.00107	0.0041	CcSEcCtD
Conivaptan—Sepsis—Methotrexate—multiple sclerosis	0.00106	0.00405	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00106	0.00478	CbGpPWpGaD
Conivaptan—Body temperature increased—Cladribine—multiple sclerosis	0.00105	0.00402	CcSEcCtD
Conivaptan—Skin disorder—Azathioprine—multiple sclerosis	0.00105	0.00402	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00105	0.00475	CbGpPWpGaD
Conivaptan—Infestation—Methylprednisolone—multiple sclerosis	0.00104	0.00394	CcSEcCtD
Conivaptan—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00104	0.00394	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00103	0.00465	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00102	0.00462	CbGpPWpGaD
Conivaptan—Hypotension—Azathioprine—multiple sclerosis	0.00101	0.00386	CcSEcCtD
Conivaptan—Polyuria—Methotrexate—multiple sclerosis	0.00101	0.00386	CcSEcCtD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00101	0.00455	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00101	0.00455	CbGpPWpGaD
Conivaptan—Anaemia—Mitoxantrone—multiple sclerosis	0.000993	0.00379	CcSEcCtD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000993	0.00449	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000993	0.00449	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000989	0.00447	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.000982	0.00444	CbGpPWpGaD
Conivaptan—Hypokalaemia—Prednisone—multiple sclerosis	0.000968	0.00369	CcSEcCtD
Conivaptan—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000953	0.00363	CcSEcCtD
Conivaptan—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000953	0.00363	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00095	0.00429	CbGpPWpGaD
Conivaptan—Pruritus—Cladribine—multiple sclerosis	0.000944	0.0036	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000943	0.00426	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000937	0.00357	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000932	0.00421	CbGpPWpGaD
Conivaptan—Hypertension—Mitoxantrone—multiple sclerosis	0.000928	0.00354	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000926	0.00418	CbGpPWpGaD
Conivaptan—Diarrhoea—Cladribine—multiple sclerosis	0.000913	0.00348	CcSEcCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000903	0.00408	CbGpPWpGaD
Conivaptan—Feeling abnormal—Azathioprine—multiple sclerosis	0.000894	0.00341	CcSEcCtD
Conivaptan—Confusional state—Mitoxantrone—multiple sclerosis	0.000884	0.00337	CcSEcCtD
Conivaptan—Erythema—Prednisolone—multiple sclerosis	0.000882	0.00336	CcSEcCtD
Conivaptan—Infection—Mitoxantrone—multiple sclerosis	0.000871	0.00332	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.000869	0.00393	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCL3—multiple sclerosis	0.000867	0.00392	CbGpPWpGaD
Conivaptan—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000863	0.00329	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CCL3—multiple sclerosis	0.00086	0.00389	CbGpPWpGaD
Conivaptan—Body temperature increased—Azathioprine—multiple sclerosis	0.000858	0.00327	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000855	0.00386	CbGpPWpGaD
Conivaptan—Skin disorder—Mitoxantrone—multiple sclerosis	0.000852	0.00325	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000849	0.00384	CbGpPWpGaD
Conivaptan—Vomiting—Cladribine—multiple sclerosis	0.000848	0.00323	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—S1PR1—multiple sclerosis	0.000847	0.00383	CbGpPWpGaD
Conivaptan—Angiopathy—Methylprednisolone—multiple sclerosis	0.000843	0.00321	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—S1PR1—multiple sclerosis	0.000841	0.0038	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000838	0.00319	CcSEcCtD
Conivaptan—Headache—Cladribine—multiple sclerosis	0.000836	0.00319	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTGER4—multiple sclerosis	0.000834	0.00377	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Prednisone—multiple sclerosis	0.00083	0.00316	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—PTGER4—multiple sclerosis	0.000828	0.00374	CbGpPWpGaD
Conivaptan—Hypotension—Mitoxantrone—multiple sclerosis	0.00082	0.00312	CcSEcCtD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000816	0.00369	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000816	0.00369	CbGpPWpGaD
Conivaptan—Mental disorder—Methylprednisolone—multiple sclerosis	0.000814	0.0031	CcSEcCtD
Conivaptan—Erythema—Triamcinolone—multiple sclerosis	0.000811	0.00309	CcSEcCtD
Conivaptan—Erythema—Methylprednisolone—multiple sclerosis	0.000809	0.00308	CcSEcCtD
Conivaptan—Malnutrition—Methylprednisolone—multiple sclerosis	0.000809	0.00308	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CXCR3—multiple sclerosis	0.000806	0.00364	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CXCR3—multiple sclerosis	0.0008	0.00361	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—RGS1—multiple sclerosis	0.000793	0.00358	CbGpPWpGaD
Conivaptan—Nausea—Cladribine—multiple sclerosis	0.000793	0.00302	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—RGS1—multiple sclerosis	0.000787	0.00356	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCR2—multiple sclerosis	0.000784	0.00354	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR2—multiple sclerosis	0.000778	0.00352	CbGpPWpGaD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000774	0.0035	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000773	0.00349	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000769	0.00347	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000768	0.00347	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000767	0.00347	CbGpPWpGaD
Conivaptan—Angiopathy—Betamethasone—multiple sclerosis	0.000767	0.00292	CcSEcCtD
Conivaptan—Angiopathy—Dexamethasone—multiple sclerosis	0.000767	0.00292	CcSEcCtD
Conivaptan—Hypertension—Prednisolone—multiple sclerosis	0.000761	0.0029	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000756	0.00342	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—GPR65—multiple sclerosis	0.000752	0.0034	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000751	0.00339	CbGpPWpGaD
Conivaptan—Constipation—Mitoxantrone—multiple sclerosis	0.00075	0.00286	CcSEcCtD
Conivaptan—Pain—Mitoxantrone—multiple sclerosis	0.00075	0.00286	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—GPR65—multiple sclerosis	0.000746	0.00337	CbGpPWpGaD
Conivaptan—Diarrhoea—Azathioprine—multiple sclerosis	0.000742	0.00283	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000736	0.00333	CbGpPWpGaD
Conivaptan—Erythema—Betamethasone—multiple sclerosis	0.000736	0.0028	CcSEcCtD
Conivaptan—Erythema—Dexamethasone—multiple sclerosis	0.000736	0.0028	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000731	0.0033	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CNR1—multiple sclerosis	0.000723	0.00327	CbGpPWpGaD
Conivaptan—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000723	0.00275	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—RGS1—multiple sclerosis	0.00072	0.00325	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CNR1—multiple sclerosis	0.000718	0.00324	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—RGS1—multiple sclerosis	0.000715	0.00323	CbGpPWpGaD
Conivaptan—Hypertension—Triamcinolone—multiple sclerosis	0.0007	0.00267	CcSEcCtD
Conivaptan—Hypertension—Methylprednisolone—multiple sclerosis	0.000699	0.00266	CcSEcCtD
Conivaptan—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000693	0.00264	CcSEcCtD
Conivaptan—Vomiting—Azathioprine—multiple sclerosis	0.00069	0.00263	CcSEcCtD
Conivaptan—Pneumonia—Methotrexate—multiple sclerosis	0.000689	0.00263	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000687	0.00311	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR1—multiple sclerosis	0.000687	0.00311	CbGpPWpGaD
Conivaptan—Infestation—Methotrexate—multiple sclerosis	0.000685	0.00261	CcSEcCtD
Conivaptan—Infestation NOS—Methotrexate—multiple sclerosis	0.000685	0.00261	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000684	0.00261	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—GPR65—multiple sclerosis	0.000682	0.00308	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000682	0.00308	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000682	0.00308	CbGpPWpGaD
Conivaptan—Headache—Azathioprine—multiple sclerosis	0.00068	0.00259	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—GPR65—multiple sclerosis	0.000678	0.00306	CbGpPWpGaD
Conivaptan—Dry mouth—Triamcinolone—multiple sclerosis	0.000675	0.00257	CcSEcCtD
Conivaptan—Angiopathy—Prednisone—multiple sclerosis	0.000668	0.00254	CcSEcCtD
Conivaptan—Confusional state—Methylprednisolone—multiple sclerosis	0.000666	0.00254	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000663	0.003	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LINGO1—multiple sclerosis	0.00066	0.00298	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000658	0.00298	CbGpPWpGaD
Conivaptan—Infection—Triamcinolone—multiple sclerosis	0.000657	0.00251	CcSEcCtD
Conivaptan—Infection—Methylprednisolone—multiple sclerosis	0.000656	0.0025	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—LINGO1—multiple sclerosis	0.000655	0.00296	CbGpPWpGaD
Conivaptan—Haematuria—Methotrexate—multiple sclerosis	0.000653	0.00249	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CXCL10—multiple sclerosis	0.000651	0.00294	CbGpPWpGaD
Conivaptan—Insomnia—Prednisolone—multiple sclerosis	0.000651	0.00248	CcSEcCtD
Conivaptan—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000648	0.00247	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000647	0.00292	CbGpPWpGaD
Conivaptan—Mental disorder—Prednisone—multiple sclerosis	0.000645	0.00246	CcSEcCtD
Conivaptan—Nausea—Azathioprine—multiple sclerosis	0.000645	0.00246	CcSEcCtD
Conivaptan—Skin disorder—Methylprednisolone—multiple sclerosis	0.000641	0.00244	CcSEcCtD
Conivaptan—Erythema—Prednisone—multiple sclerosis	0.000641	0.00244	CcSEcCtD
Conivaptan—Malnutrition—Prednisone—multiple sclerosis	0.000641	0.00244	CcSEcCtD
Conivaptan—Hypertension—Dexamethasone—multiple sclerosis	0.000635	0.00242	CcSEcCtD
Conivaptan—Hypertension—Betamethasone—multiple sclerosis	0.000635	0.00242	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL13—multiple sclerosis	0.000624	0.00282	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCR1—multiple sclerosis	0.000624	0.00282	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000622	0.00281	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCR1—multiple sclerosis	0.00062	0.0028	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CXCL13—multiple sclerosis	0.00062	0.0028	CbGpPWpGaD
Conivaptan—Hypotension—Methylprednisolone—multiple sclerosis	0.000617	0.00235	CcSEcCtD
Conivaptan—Pain—Prednisolone—multiple sclerosis	0.000615	0.00234	CcSEcCtD
Conivaptan—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000607	0.00231	CcSEcCtD
Conivaptan—Urethral disorder—Methotrexate—multiple sclerosis	0.000603	0.0023	CcSEcCtD
Conivaptan—Diarrhoea—Mitoxantrone—multiple sclerosis	0.0006	0.00229	CcSEcCtD
Conivaptan—Insomnia—Triamcinolone—multiple sclerosis	0.000599	0.00228	CcSEcCtD
Conivaptan—Insomnia—Methylprednisolone—multiple sclerosis	0.000597	0.00228	CcSEcCtD
Conivaptan—Infection—Betamethasone—multiple sclerosis	0.000597	0.00227	CcSEcCtD
Conivaptan—Infection—Dexamethasone—multiple sclerosis	0.000597	0.00227	CcSEcCtD
Conivaptan—Feeling abnormal—Prednisolone—multiple sclerosis	0.000593	0.00226	CcSEcCtD
Conivaptan—Anaemia—Prednisone—multiple sclerosis	0.000592	0.00226	CcSEcCtD
Conivaptan—Nervous system disorder—Betamethasone—multiple sclerosis	0.000589	0.00224	CcSEcCtD
Conivaptan—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000589	0.00224	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—TAGAP—multiple sclerosis	0.000572	0.00259	CbGpPWpGaD
Conivaptan—Cardiac disorder—Methotrexate—multiple sclerosis	0.000571	0.00218	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—TAGAP—multiple sclerosis	0.000568	0.00257	CbGpPWpGaD
Conivaptan—Pain—Triamcinolone—multiple sclerosis	0.000566	0.00216	CcSEcCtD
Conivaptan—Hypotension—Betamethasone—multiple sclerosis	0.000561	0.00214	CcSEcCtD
Conivaptan—Hypotension—Dexamethasone—multiple sclerosis	0.000561	0.00214	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CCL5—multiple sclerosis	0.000561	0.00253	CbGpPWpGaD
Conivaptan—Angiopathy—Methotrexate—multiple sclerosis	0.000558	0.00213	CcSEcCtD
Conivaptan—Vomiting—Mitoxantrone—multiple sclerosis	0.000558	0.00213	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—CCL5—multiple sclerosis	0.000557	0.00251	CbGpPWpGaD
Conivaptan—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000554	0.00211	CcSEcCtD
Conivaptan—Hypertension—Prednisone—multiple sclerosis	0.000553	0.00211	CcSEcCtD
Conivaptan—Headache—Mitoxantrone—multiple sclerosis	0.00055	0.00209	CcSEcCtD
Conivaptan—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000545	0.00208	CcSEcCtD
Conivaptan—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000544	0.00207	CcSEcCtD
Conivaptan—Insomnia—Betamethasone—multiple sclerosis	0.000543	0.00207	CcSEcCtD
Conivaptan—Insomnia—Dexamethasone—multiple sclerosis	0.000543	0.00207	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000542	0.00206	CcSEcCtD
Conivaptan—Mental disorder—Methotrexate—multiple sclerosis	0.000539	0.00205	CcSEcCtD
Conivaptan—Erythema—Methotrexate—multiple sclerosis	0.000535	0.00204	CcSEcCtD
Conivaptan—Malnutrition—Methotrexate—multiple sclerosis	0.000535	0.00204	CcSEcCtD
Conivaptan—Body temperature increased—Triamcinolone—multiple sclerosis	0.000523	0.00199	CcSEcCtD
Conivaptan—Nausea—Mitoxantrone—multiple sclerosis	0.000521	0.00199	CcSEcCtD
Conivaptan—Infection—Prednisone—multiple sclerosis	0.00052	0.00198	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000519	0.00234	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000518	0.00198	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000518	0.00198	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000518	0.00234	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000515	0.00233	CbGpPWpGaD
Conivaptan—Pain—Betamethasone—multiple sclerosis	0.000513	0.00196	CcSEcCtD
Conivaptan—Pain—Dexamethasone—multiple sclerosis	0.000513	0.00196	CcSEcCtD
Conivaptan—Nervous system disorder—Prednisone—multiple sclerosis	0.000513	0.00195	CcSEcCtD
Conivaptan—Skin disorder—Prednisone—multiple sclerosis	0.000508	0.00194	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000507	0.00229	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCR5—multiple sclerosis	0.000505	0.00228	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000504	0.00228	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCR5—multiple sclerosis	0.000501	0.00227	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—S1PR1—multiple sclerosis	0.0005	0.00226	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—S1PR1—multiple sclerosis	0.000497	0.00224	CbGpPWpGaD
Conivaptan—Anaemia—Methotrexate—multiple sclerosis	0.000495	0.00189	CcSEcCtD
Conivaptan—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000495	0.00189	CcSEcCtD
Conivaptan—Feeling abnormal—Betamethasone—multiple sclerosis	0.000495	0.00189	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—GPC5—multiple sclerosis	0.000487	0.0022	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GPC5—multiple sclerosis	0.000483	0.00218	CbGpPWpGaD
Conivaptan—Body temperature increased—Betamethasone—multiple sclerosis	0.000475	0.00181	CcSEcCtD
Conivaptan—Body temperature increased—Dexamethasone—multiple sclerosis	0.000475	0.00181	CcSEcCtD
Conivaptan—Insomnia—Prednisone—multiple sclerosis	0.000473	0.0018	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000471	0.00213	CbGpPWpGaD
Conivaptan—Pruritus—Triamcinolone—multiple sclerosis	0.000468	0.00178	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000468	0.00211	CbGpPWpGaD
Conivaptan—Pruritus—Methylprednisolone—multiple sclerosis	0.000467	0.00178	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000455	0.00206	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000453	0.00173	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000452	0.00204	CbGpPWpGaD
Conivaptan—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000452	0.00172	CcSEcCtD
Conivaptan—Headache—Prednisolone—multiple sclerosis	0.000451	0.00172	CcSEcCtD
Conivaptan—Constipation—Prednisone—multiple sclerosis	0.000447	0.0017	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCL3—multiple sclerosis	0.000445	0.00201	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR2—multiple sclerosis	0.000443	0.002	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCL3—multiple sclerosis	0.000442	0.002	CbGpPWpGaD
Conivaptan—Confusional state—Methotrexate—multiple sclerosis	0.000441	0.00168	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CCR2—multiple sclerosis	0.00044	0.00199	CbGpPWpGaD
Conivaptan—Infection—Methotrexate—multiple sclerosis	0.000434	0.00165	CcSEcCtD
Conivaptan—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000433	0.00196	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000433	0.00196	CbGpPWpGaD
Conivaptan—Feeling abnormal—Prednisone—multiple sclerosis	0.000431	0.00164	CcSEcCtD
Conivaptan—Nervous system disorder—Methotrexate—multiple sclerosis	0.000429	0.00163	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—PTGER4—multiple sclerosis	0.000428	0.00193	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000428	0.00193	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000428	0.00193	CbGpPWpGaD
Conivaptan—Nausea—Prednisolone—multiple sclerosis	0.000427	0.00163	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—RGS1—multiple sclerosis	0.000425	0.00192	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTGER4—multiple sclerosis	0.000425	0.00192	CbGpPWpGaD
Conivaptan—Pruritus—Dexamethasone—multiple sclerosis	0.000425	0.00162	CcSEcCtD
Conivaptan—Pruritus—Betamethasone—multiple sclerosis	0.000425	0.00162	CcSEcCtD
Conivaptan—Skin disorder—Methotrexate—multiple sclerosis	0.000425	0.00162	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—RGS1—multiple sclerosis	0.000422	0.00191	CbGpPWpGaD
Conivaptan—Vomiting—Triamcinolone—multiple sclerosis	0.000421	0.0016	CcSEcCtD
Conivaptan—Vomiting—Methylprednisolone—multiple sclerosis	0.00042	0.0016	CcSEcCtD
Conivaptan—Headache—Triamcinolone—multiple sclerosis	0.000415	0.00158	CcSEcCtD
Conivaptan—Headache—Methylprednisolone—multiple sclerosis	0.000414	0.00158	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CXCR3—multiple sclerosis	0.000413	0.00187	CbGpPWpGaD
Conivaptan—Body temperature increased—Prednisone—multiple sclerosis	0.000413	0.00158	CcSEcCtD
Conivaptan—Diarrhoea—Dexamethasone—multiple sclerosis	0.000411	0.00157	CcSEcCtD
Conivaptan—Diarrhoea—Betamethasone—multiple sclerosis	0.000411	0.00157	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CXCR3—multiple sclerosis	0.000411	0.00185	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CNR1—multiple sclerosis	0.000409	0.00185	CbGpPWpGaD
Conivaptan—Hypotension—Methotrexate—multiple sclerosis	0.000408	0.00156	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—CNR1—multiple sclerosis	0.000406	0.00183	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GPR65—multiple sclerosis	0.000403	0.00182	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCR2—multiple sclerosis	0.000402	0.00182	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GPR65—multiple sclerosis	0.0004	0.00181	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCR2—multiple sclerosis	0.000399	0.0018	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	0.000396	0.00179	CbGpPWpGaD
Conivaptan—Insomnia—Methotrexate—multiple sclerosis	0.000395	0.00151	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—POMC—multiple sclerosis	0.000395	0.00178	CbGpPWpGaD
Conivaptan—Nausea—Triamcinolone—multiple sclerosis	0.000393	0.0015	CcSEcCtD
Conivaptan—Nausea—Methylprednisolone—multiple sclerosis	0.000392	0.00149	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—POMC—multiple sclerosis	0.000392	0.00177	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CCL2—multiple sclerosis	0.000386	0.00175	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CCL2—multiple sclerosis	0.000383	0.00173	CbGpPWpGaD
Conivaptan—Vomiting—Betamethasone—multiple sclerosis	0.000382	0.00145	CcSEcCtD
Conivaptan—Vomiting—Dexamethasone—multiple sclerosis	0.000382	0.00145	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000377	0.00144	CcSEcCtD
Conivaptan—Headache—Betamethasone—multiple sclerosis	0.000376	0.00143	CcSEcCtD
Conivaptan—Headache—Dexamethasone—multiple sclerosis	0.000376	0.00143	CcSEcCtD
Conivaptan—Pain—Methotrexate—multiple sclerosis	0.000374	0.00142	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CNR1—multiple sclerosis	0.000371	0.00168	CbGpPWpGaD
Conivaptan—Pruritus—Prednisone—multiple sclerosis	0.00037	0.00141	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CXCL13—multiple sclerosis	0.000369	0.00167	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR1—multiple sclerosis	0.000369	0.00167	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CNR1—multiple sclerosis	0.000369	0.00167	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000368	0.00166	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL13—multiple sclerosis	0.000366	0.00165	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR1—multiple sclerosis	0.000366	0.00165	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000365	0.00165	CbGpPWpGaD
Conivaptan—Feeling abnormal—Methotrexate—multiple sclerosis	0.00036	0.00137	CcSEcCtD
Conivaptan—Diarrhoea—Prednisone—multiple sclerosis	0.000358	0.00136	CcSEcCtD
Conivaptan—Nausea—Betamethasone—multiple sclerosis	0.000357	0.00136	CcSEcCtD
Conivaptan—Nausea—Dexamethasone—multiple sclerosis	0.000357	0.00136	CcSEcCtD
Conivaptan—Body temperature increased—Methotrexate—multiple sclerosis	0.000345	0.00132	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CXCL10—multiple sclerosis	0.000334	0.00151	CbGpPWpGaD
Conivaptan—Vomiting—Prednisone—multiple sclerosis	0.000332	0.00127	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—CXCL10—multiple sclerosis	0.000332	0.0015	CbGpPWpGaD
Conivaptan—Headache—Prednisone—multiple sclerosis	0.000328	0.00125	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—CCL5—multiple sclerosis	0.000317	0.00143	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCL5—multiple sclerosis	0.000315	0.00142	CbGpPWpGaD
Conivaptan—Nausea—Prednisone—multiple sclerosis	0.000311	0.00118	CcSEcCtD
Conivaptan—Pruritus—Methotrexate—multiple sclerosis	0.000309	0.00118	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	0.000304	0.00137	CbGpPWpGaD
Conivaptan—Diarrhoea—Methotrexate—multiple sclerosis	0.000299	0.00114	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCL5—multiple sclerosis	0.000288	0.0013	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCL5—multiple sclerosis	0.000286	0.00129	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CCR5—multiple sclerosis	0.000285	0.00129	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CCR5—multiple sclerosis	0.000283	0.00128	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000281	0.00127	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000279	0.00126	CbGpPWpGaD
Conivaptan—Vomiting—Methotrexate—multiple sclerosis	0.000278	0.00106	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000277	0.00125	CbGpPWpGaD
Conivaptan—Headache—Methotrexate—multiple sclerosis	0.000274	0.00104	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CCL3—multiple sclerosis	0.000263	0.00119	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL3—multiple sclerosis	0.000261	0.00118	CbGpPWpGaD
Conivaptan—Nausea—Methotrexate—multiple sclerosis	0.00026	0.000989	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CCR5—multiple sclerosis	0.000259	0.00117	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCR5—multiple sclerosis	0.000257	0.00116	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2RA—multiple sclerosis	0.000255	0.00115	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2RA—multiple sclerosis	0.000254	0.00115	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTGER4—multiple sclerosis	0.000253	0.00114	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTGER4—multiple sclerosis	0.000251	0.00113	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PGR—multiple sclerosis	0.000249	0.00113	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PGR—multiple sclerosis	0.000247	0.00112	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCR3—multiple sclerosis	0.000244	0.0011	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCR3—multiple sclerosis	0.000243	0.0011	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CD28—multiple sclerosis	0.000242	0.00109	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CD28—multiple sclerosis	0.00024	0.00109	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR2—multiple sclerosis	0.000238	0.00107	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR2—multiple sclerosis	0.000236	0.00107	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000226	0.00102	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—POMC—multiple sclerosis	0.000223	0.00101	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—POMC—multiple sclerosis	0.000221	0.001	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CNR1—multiple sclerosis	0.000219	0.000991	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CNR1—multiple sclerosis	0.000218	0.000984	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—POMC—multiple sclerosis	0.000203	0.000915	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—POMC—multiple sclerosis	0.000201	0.000909	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CCL2—multiple sclerosis	0.000198	0.000896	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CXCL10—multiple sclerosis	0.000197	0.000892	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CCL2—multiple sclerosis	0.000197	0.000889	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CXCL10—multiple sclerosis	0.000196	0.000886	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000184	0.000829	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—TYK2—multiple sclerosis	0.00018	0.000813	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—TYK2—multiple sclerosis	0.000179	0.000807	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CD86—multiple sclerosis	0.000173	0.00078	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CD86—multiple sclerosis	0.000171	0.000774	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCL5—multiple sclerosis	0.00017	0.000768	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL5—multiple sclerosis	0.000169	0.000762	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—multiple sclerosis	0.000165	0.000745	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—multiple sclerosis	0.000164	0.00074	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SPP1—multiple sclerosis	0.000157	0.000711	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SPP1—multiple sclerosis	0.000156	0.000706	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCR5—multiple sclerosis	0.000153	0.000692	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCR5—multiple sclerosis	0.000152	0.000687	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2RA—multiple sclerosis	0.000151	0.000682	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2RA—multiple sclerosis	0.00015	0.000677	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—multiple sclerosis	0.00015	0.000677	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—multiple sclerosis	0.000149	0.000672	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—APOE—multiple sclerosis	0.000139	0.000629	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—APOE—multiple sclerosis	0.000138	0.000625	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CD80—multiple sclerosis	0.000126	0.000569	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CD80—multiple sclerosis	0.000125	0.000565	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—POMC—multiple sclerosis	0.00012	0.000541	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—POMC—multiple sclerosis	0.000119	0.000537	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCL2—multiple sclerosis	0.000117	0.000529	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCL2—multiple sclerosis	0.000116	0.000525	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—MAPK1—multiple sclerosis	0.000115	0.000518	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MAPK1—multiple sclerosis	0.000114	0.000514	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TYK2—multiple sclerosis	0.000106	0.00048	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TYK2—multiple sclerosis	0.000106	0.000477	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SRM—multiple sclerosis	0.000105	0.000475	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—POMC—multiple sclerosis	9.75e-05	0.000441	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—multiple sclerosis	8.85e-05	0.0004	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—multiple sclerosis	8.8e-05	0.000398	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—multiple sclerosis	8.78e-05	0.000397	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—multiple sclerosis	8.74e-05	0.000395	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MMP9—multiple sclerosis	8.37e-05	0.000378	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MMP9—multiple sclerosis	8.31e-05	0.000376	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—STAT3—multiple sclerosis	7.44e-05	0.000336	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	7.41e-05	0.000335	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	7.41e-05	0.000335	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—STAT3—multiple sclerosis	7.39e-05	0.000334	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—multiple sclerosis	6.92e-05	0.000313	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—multiple sclerosis	6.9e-05	0.000312	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—multiple sclerosis	6.87e-05	0.00031	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—multiple sclerosis	6.85e-05	0.00031	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPC5—multiple sclerosis	6.78e-05	0.000306	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK1—multiple sclerosis	6.77e-05	0.000306	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK1—multiple sclerosis	6.72e-05	0.000304	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RRM1—multiple sclerosis	5.62e-05	0.000254	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—multiple sclerosis	5.2e-05	0.000235	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—multiple sclerosis	5.16e-05	0.000233	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.23e-05	0.000146	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—APOE—multiple sclerosis	1.94e-05	8.77e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—POMC—multiple sclerosis	1.67e-05	7.53e-05	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALB—multiple sclerosis	1.52e-05	6.87e-05	CbGpPWpGaD
